2024
Mechanisms of therapeutic change after psychedelic treatment in OCD
Maloney G, Ching T, Kichuk S, Pittenger C, Kelmendi B. Mechanisms of therapeutic change after psychedelic treatment in OCD. Psychiatry Research 2024, 336: 115907. PMID: 38615521, PMCID: PMC11190873, DOI: 10.1016/j.psychres.2024.115907.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderMechanisms of therapeutic changeAversive eventsImagery rescriptingPsychedelic treatmentPsychotherapeutic treatmentPsychotherapeutic frameworkSymptom reductionTherapeutic changePsychotherapyNegative emotionsPsychological mechanismsCore beliefsPilot dataNovel treatmentRescriptingEmotionsDisordersSymptomsReprocessingTreatmentBeliefsResistance to first-lineIndividualsInterventionCorrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 15: 1372373. PMID: 38435972, PMCID: PMC10905264, DOI: 10.3389/fpsyt.2024.1372373.Peer-Reviewed Original ResearchSafety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D’Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 14: 1278823. PMID: 38264632, PMCID: PMC10803438, DOI: 10.3389/fpsyt.2023.1278823.Peer-Reviewed Original ResearchObsessive-compulsive disorderPrimary outcomeNon-directive supportClinical effectsTreatment-refractory obsessive-compulsive disorderRefractory obsessive-compulsive disorderSingle-dose trialBlinded ratingsWaitlist-controlled trialDose selection strategiesOCD symptom reductionTreatment of OCDEffects of psilocybinSingle-site trialOCD symptomsInstitutional review boardBlinded independent ratersTrials of psilocybinYale-Brown ObsessiveWaitlist control designPrimary endpointMore dosesFuture trialsSingle dosePsilocybin treatment
2023
Neurofeedback for obsessive compulsive disorder: A randomized, double-blind trial
Rance M, Zhao Z, Zaboski B, Kichuk S, Romaker E, Koller W, Walsh C, Harris-Starling C, Wasylink S, Adams T, Gruner P, Pittenger C, Hampson M. Neurofeedback for obsessive compulsive disorder: A randomized, double-blind trial. Psychiatry Research 2023, 328: 115458. PMID: 37722238, PMCID: PMC10695074, DOI: 10.1016/j.psychres.2023.115458.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAnterior prefrontal cortexControl groupDouble-blind clinical trialDouble-blind trialPrimary outcome measureCompulsive disorderHarm/checkingMechanism of actionYale-Brown ObsessiveSecondary outcomesSessions of neurofeedbackActive groupClinical trialsOutcome measuresPrimary symptomsSymptom ScaleObsessive-compulsive symptomsPrefrontal cortexSymptomsTraining protocolGreater reductionSignificant differencesPatientsSham feedbackSafety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
Ching T, Grazioplene R, Bohner C, Kichuk S, DePalmer G, D’Amico E, Eilbott J, Jankovsky A, Burke M, Hokanson J, Martins B, Witherow C, Patel P, Amoroso L, Schaer H, Pittenger C, Kelmendi B. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Frontiers In Psychiatry 2023, 14: 1178529. PMID: 37181888, PMCID: PMC10166878, DOI: 10.3389/fpsyt.2023.1178529.Peer-Reviewed Original ResearchObsessive-compulsive disorderPrimary endpointPsilocybin effectsNeural effectsRefractory obsessive-compulsive disorderNon-crossover designOpen-label doseStandard care treatmentOpen-label studyVisual analog scale ratingsTreatment of OCDEffects of psilocybinOCD symptomsInstitutional review boardYale-Brown ObsessivePrimary outcomeSingle doseCare treatmentOral psilocybinInformed consentReview boardNeurobiological mechanismsCompulsive ScalePsychological supportTrials
2022
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi B, Kichuk S, DePalmer G, Maloney G, Ching T, Belser A, Pittenger C. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon 2022, 8: e12135. PMID: 36536916, PMCID: PMC9758406, DOI: 10.1016/j.heliyon.2022.e12135.Peer-Reviewed Original ResearchObsessive-compulsive disorderTreatment of OCDPsychedelic treatmentTreatment-resistant obsessive-compulsive disorderRefractory obsessive-compulsive disorderOCD symptomsPsychological effectsSerotonin systemSingle experimental studyRecreational usersBrain serotonin systemTreatment of patientsClassic psychedelicsQuality of lifePsilocybinSymptomatic improvementCase reportClinical dataTherapeutic potentialEmotionsPatientsDisordersTreatmentNumber of conditionsCompulsion
2021
Transcranial direct current stimulation targeting the medial prefrontal cortex modulates functional connectivity and enhances safety learning in obsessive‐compulsive disorder: Results from two pilot studies
Adams TG, Cisler JM, Kelmendi B, George JR, Kichuk SA, Averill CL, Anticevic A, Abdallah CG, Pittenger C. Transcranial direct current stimulation targeting the medial prefrontal cortex modulates functional connectivity and enhances safety learning in obsessive‐compulsive disorder: Results from two pilot studies. Depression And Anxiety 2021, 39: 37-48. PMID: 34464485, PMCID: PMC8732293, DOI: 10.1002/da.23212.Peer-Reviewed Original ResearchConceptsTranscranial direct current stimulationMedial prefrontal cortexDefault mode networkObsessive-compulsive disorderDirect current stimulationFunctional connectivityCurrent stimulationSham transcranial direct current stimulationResting-state functional magnetic resonanceSafety learningActive transcranial direct current stimulationEffects of tDCSMainstay of treatmentCommunity volunteersExposure-based psychotherapySuperior frontal gyrusFunctional magnetic resonanceBasal gangliaClinical trialsExposure-based therapyVivo exposureSalience networkSubjective emotional distressAnterior insulaPrefrontal cortex
2018
Developing image sets for inducing obsessive-compulsive checking symptoms
Brooks H, Kichuk SA, Adams TG, Koller WN, Eken HN, Rance M, Monahan S, Wasylink S, Kelmendi B, Pittenger C, Gruner P, Hampson M. Developing image sets for inducing obsessive-compulsive checking symptoms. Psychiatry Research 2018, 265: 249-255. PMID: 29763844, PMCID: PMC6063514, DOI: 10.1016/j.psychres.2018.04.035.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderProvocative imagesSymptom provocationDiagnosis of OCDClinical obsessive-compulsive disorderInduction of anxietyContextual cuesIntrusive thoughtsVisual stimuliOC symptomsCompulsive disorderDiagnostic statusAnxietyStimuliHarmful scenariosSimilar objectsGreat provocationsIndividualsSuggestive imagesProvocationQualitative patternCuesSymptomsResearch studiesFuture studies
2016
OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding
Pittenger C, Adams TG, Gallezot JD, Crowley MJ, Nabulsi N, Ropchan J, Gao H, Kichuk SA, Simpson R, Billingslea E, Hannestad J, Bloch M, Mayes L, Bhagwagar Z, Carson RE. OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding. Journal Of Affective Disorders 2016, 196: 87-96. PMID: 26919057, PMCID: PMC4808438, DOI: 10.1016/j.jad.2016.02.021.Peer-Reviewed Original ResearchConceptsPrepulse inhibitionObsessive-compulsive disorderReceptor availabilitySensorimotor gatingOCD patientsImpaired sensorimotor gatingOCD-like behaviorNon-depressed OCD patientsPositron emission tomographyBasal gangliaSerotonergic regulationHealthy controlsSerotonin systemPositive correlationWidespread positive correlationsDiagnostic groupsCortical regionsEmission tomographyOrbitofrontal cortexPatientsReceptor bindingOCD diagnosisSignificant correlationSignificant main effectImportant alterations
2013
LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER
Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros‐Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, Coric V, Pittenger C. LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER. Depression And Anxiety 2013, 30: 716-722. PMID: 23532944, PMCID: PMC3932438, DOI: 10.1002/da.22103.Peer-Reviewed Original ResearchConceptsLong-term outcomesObsessive-compulsive disorderEvidence-based treatmentsAdult OCD patientsLong-term clinical outcomesSymptom severitySerotonin reuptake inhibitor medicationsOCD patientsPlacebo-controlled trialSerotonin reuptake inhibitorsReuptake inhibitor medicationsPercent of subjectsInitial responseSymptom dimensionsLater symptom severityOCD symptomsSignificant OCD symptomsOCD symptom dimensionsAdult patientsClinical characteristicsClinical improvementEligible subjectsPartial respondersInhibitor medicationReuptake inhibitorsSymptom dimensions are associated with age of onset and clinical course of obsessive–compulsive disorder
Kichuk SA, Torres AR, Fontenelle LF, Rosário MC, Shavitt RG, Miguel EC, Pittenger C, Bloch MH. Symptom dimensions are associated with age of onset and clinical course of obsessive–compulsive disorder. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2013, 44: 233-239. PMID: 23410525, PMCID: PMC3654083, DOI: 10.1016/j.pnpbp.2013.02.003.Peer-Reviewed Original ResearchConceptsAge of onsetClinical courseObsessive-compulsive disorderPrimary symptom dimensionsSymptom dimensionsPrimary OCD symptomsChi-square testEarly ageOCD symptom dimensionsYale-Brown ObsessiveAdult patientsComorbid ticsSignificant symptomsLarge cohortDifferent OCD symptom dimensionsHeterogeneous symptomsSymptomsCompulsive ScaleDimensional Yale-Brown ObsessiveAgeSignificant differencesOCD symptomsOnsetInconsistent results